期刊文献+

HCMV感染对多种机会性病毒感染的影响

The influence of HCMV infection on opportunistic virus infections
下载PDF
导出
摘要 目的探究肾移植前人巨细胞病毒(human cytomegalovirus,HCMV)感染对移植后多种机会性病毒(HCMV、多瘤BK病毒(BK virus,BKV)、多瘤JC病毒(JC virus,JCV)、乙型肝炎病毒(hepatitis B virus,HBV)、丙型肝炎病毒(Hepatitis C virus,HCV))机会性感染的影响。方法采用免疫组化方法检测肾移植病人移植前后外周血HCMV被膜抗原pp65,巢式PCR方法检测病人尿液标本中的BKV DNA、JCV DNA;ELISA方法检测病人血液标本中的HBV抗原、抗体和HCV丙肝抗体(Anti-HCV);根据移植前有无感染HCMV将病人分为HCMV感染组和非感染组。结果 HCMV感染组与非感染组移植后HCMV、JCV、BKV、HBV、HCV感染率分别为20%与2.8%(P=0.049)、50%与19.4%(P=0.017)、0%与8.3%(P=0.545)、0%与13.9%(P=0.144)、0%与3.0%(P=1.000)。结论肾移植前HCMV感染不仅可引起移植后HCMV再激活感染,还可转化激活JCV的复制和感染。 Objective To investigate the impact of HCMV infection before transplantation on opportunistic virus infections after renal transplantation.Methods HCMV pp65 antigenemia was detected using immunohistochemical method of plasma;BKV DNA and JCV DNA were measured using nested qualitative polymerase chain reaction assays of urine;HBV antigen,antibody and anti-HCV were measured by enzyme linked immunosorbent assay(ELISA).According to whether HCMV infected or not before transplantation,all patients were divided into two groups(HCMV-infected group and un-infected group).Results The rates of HCMV,JCV,BKV,HBV and HCV infections were 20% vs 2.8%(P=0.049),50% vs 19.4%(P=0.017),0% vs 8.3%(P=0.545),0% vs 13.9%(P=0.144)and 0% vs 3.0%(P=1.000).Conclusion HCMV infection before transplantation not only has effect on HCMV reinfection,but also on JCV infection.
出处 《浙江检验医学》 2011年第2期14-17,共4页 Zhejiang Journal of Laboratory Medicine
基金 浙江省医药卫生科学项目(2008A007)
关键词 人巨细胞病毒 BK病毒 JC病毒 移植 感染 Human Cytomegalovirus BK virus JC virus Transplantation Infection
  • 相关文献

参考文献15

  • 1Sang-Oh Lee,Raymund R Razonable.Current concepts on cytomegalovirus infection after liver transplantation[J].World Journal of Hepatology,2010,2(9):325-336. 被引量:6
  • 2Miller DM,Zhang Y,Rahill BM,et al.Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory re-sponses by blocking multiple levels of IFN-alpha signal transduction. J Immunol . 1999
  • 3Randhawa P,Shapiro R,Vats A.Quantitation of DNA of polyomaviruses BK and JC in human kidneys. The Journal of Infectious Diseases . 2005
  • 4Heilbronn R,Albrecht I,Stephan S,et al.Human cytomegalovir-us induces JC virus DNAreplication in human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America . 1993
  • 5Gandhi MK,Khanna R.Human cytomegalovirus:clinical as-pects,immune regulation,and emerging treatments. Lancet In-fect Dis . 2004
  • 6Munoz P,Fogeda M,Bouza E,et al.Prevalence of BK virus repli-cation among recipients of solid organ transplants. Clinical Infectious Diseases . 2005
  • 7Vinod PB,Sharma RK.Opportunistic infections (non-cytomega-lovirus)in live related renal transplant recipients. Indian Journal of Urology . 2009
  • 8Husain S,Pietrangeli CE,Zeevi A.Delayed onset CMVdisease in solid organ transplant recipients. Transplant Immunology . 2009
  • 9Randhawa P,Uhrmacher J,Pasculle W,et al.Acomparative study of BK and JC virus infections in organ transplant recipients. Journal of Medical Virology . 2005
  • 10Lautenschlager I,Halme L,Hockerstedt K,et al.Cytomegalovirus infection of the liver transplant; virological, histological, immunological,and clinical observations. Transplant Infectious Disease . 2006

二级参考文献92

  • 1Sarmiento JM,Dockrell DH,Schwab TR,et al.Mycophenolate mofetil increases cytomegalovirces invasive organ disease in renal transplant patients. Clinical Transplantation . 2000
  • 2Humar A,Snydman D.Cytomegalovirus in solid organ transplant recipients. American Journal of Transplantation . 2009
  • 3R R Razonable,A Rivero,A Rodriguez,et al.Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. The Journal of Infectious Diseases . 2001
  • 4Razonable RR,Emery VC.Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes . 2004
  • 5Razonable RR,,Paya CV.Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes . 2003
  • 6Razonable RR,Paya CV.Infections and allograft rejection-intertwined complications of organ transplantation. Swiss Medical Weekly . 2005
  • 7Arthurs SK,Eid AJ,Pedersen RA,Kremers WK,Cosio FG,Patel R,Razonable RR.Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clinical Infectious Diseases . 2008
  • 8Gane E,Saliba F,Valdecasas GJ,O’Grady J,Pescovitz MD,Lyman S,Robinson CA.Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients.The Oral Ganciclovir International Transplantation Study Group[corrected]. The Lancet . 1997
  • 9Fica A,Cervera C,Pérez N,Marcos MA,Ramírez J,Linares L,Soto G,Navasa M,Cofan F,Ricart MJ,Pérez-Villa F,Pu-marola T,Moreno A.Immunohistochemically proven cyto-megalovirus end-organ disease in solid organ transplant patients:clinical features and usefulness of conventional diagno stic tests. Transplant Infectious Disease . 2007
  • 10Razonable RR,van Cruijsen H,Brown RA,Wilson JA,Harmsen WS,Wiesner RH,Smith TF,Paya CV.Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. The Journal of Infectious Diseases . 2003

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部